HRP20220519T1 - Kombinacijska terapija ishemije - Google Patents
Kombinacijska terapija ishemije Download PDFInfo
- Publication number
- HRP20220519T1 HRP20220519T1 HRP20220519TT HRP20220519T HRP20220519T1 HR P20220519 T1 HRP20220519 T1 HR P20220519T1 HR P20220519T T HRP20220519T T HR P20220519TT HR P20220519 T HRP20220519 T HR P20220519T HR P20220519 T1 HRP20220519 T1 HR P20220519T1
- Authority
- HR
- Croatia
- Prior art keywords
- psd
- inhibitor
- ischemia
- intended
- accordance
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 title claims 19
- 238000002648 combination therapy Methods 0.000 title 1
- 229940123119 PSD-95 Inhibitor Drugs 0.000 claims 24
- 230000010410 reperfusion Effects 0.000 claims 19
- 238000002560 therapeutic procedure Methods 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000003527 fibrinolytic agent Substances 0.000 claims 7
- 229960000103 thrombolytic agent Drugs 0.000 claims 7
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 5
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000000254 damaging effect Effects 0.000 claims 4
- 206010061216 Infarction Diseases 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 230000007574 infarction Effects 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 1
- 108010039185 Tenecteplase Proteins 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000008384 membrane barrier Effects 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960002917 reteplase Drugs 0.000 claims 1
- 108010051412 reteplase Proteins 0.000 claims 1
- 229960005202 streptokinase Drugs 0.000 claims 1
- 229960000216 tenecteplase Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Dermatology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501117P | 2011-06-24 | 2011-06-24 | |
| US201261617001P | 2012-03-28 | 2012-03-28 | |
| EP18190827.8A EP3427748B1 (en) | 2011-06-24 | 2012-06-23 | Combination therapy for ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220519T1 true HRP20220519T1 (hr) | 2022-05-27 |
Family
ID=47423033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220519TT HRP20220519T1 (hr) | 2011-06-24 | 2012-06-23 | Kombinacijska terapija ishemije |
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2012-06-23 | Kombinacijska terapija ishemije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2012-06-23 | Kombinacijska terapija ishemije |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10064910B2 (enExample) |
| EP (3) | EP3427748B1 (enExample) |
| JP (5) | JP6401057B2 (enExample) |
| KR (5) | KR102022116B1 (enExample) |
| CN (1) | CN103648518B (enExample) |
| AU (1) | AU2012274910B2 (enExample) |
| CA (1) | CA2839630A1 (enExample) |
| CY (1) | CY1121379T1 (enExample) |
| DK (2) | DK2723363T3 (enExample) |
| ES (2) | ES2690994T3 (enExample) |
| HR (2) | HRP20220519T1 (enExample) |
| HU (2) | HUE058238T2 (enExample) |
| LT (1) | LT2723363T (enExample) |
| PL (2) | PL2723363T3 (enExample) |
| PT (2) | PT3427748T (enExample) |
| RS (1) | RS57798B1 (enExample) |
| SI (1) | SI2723363T1 (enExample) |
| SM (1) | SMT201800592T1 (enExample) |
| WO (1) | WO2012176172A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1010718A2 (pt) | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
| KR102022116B1 (ko) * | 2011-06-24 | 2019-09-18 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| CZ2012476A3 (cs) * | 2012-07-12 | 2014-01-22 | Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. | Lipidované peptidy jako antiobezitika |
| US10220008B2 (en) | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
| EP3074030A4 (en) * | 2013-11-26 | 2017-08-16 | Trustees of Dartmouth College | Method for mitigating or alleviating synaptic and cognitive deficits |
| FR3021319B1 (fr) * | 2014-05-22 | 2018-08-31 | Sederma | Peptides, compositions les comprenant et utilisations notamment cosmetiques |
| CZ309217B6 (cs) * | 2014-05-27 | 2022-06-01 | Ústav Organické Chemie A Biochemie Av Čr, V.V.I. | Lipidované peptidy jako neuroprotektiva |
| KR102605540B1 (ko) | 2014-05-28 | 2023-11-22 | 노노 인코포레이티드 | Tat-nr2b9c의 클로라이드 염 |
| US9526768B2 (en) | 2014-11-13 | 2016-12-27 | Jennifer Mai | Compositions for the treatment of cancer |
| CN104497106B (zh) * | 2014-12-05 | 2017-05-10 | 华中科技大学 | 一种小分子多肽、其应用及产品 |
| KR20180135493A (ko) * | 2016-04-27 | 2018-12-20 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 흥분성 신경독성 관련 손상의 치료 방법 |
| ES2869300T3 (es) * | 2016-04-27 | 2021-10-25 | Biocells Beijing Biotech Co Ltd | Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora |
| CN107312069B (zh) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽 |
| CN107446016A (zh) * | 2016-05-30 | 2017-12-08 | 上海交通大学 | 一种硬脂酸修饰的细胞穿膜肽及其制备与应用 |
| CN106265594B (zh) * | 2016-09-21 | 2019-07-26 | 南京医科大学 | 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法 |
| CN106749559B (zh) * | 2016-11-23 | 2020-09-04 | 郑州大学 | 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法 |
| JP7109958B2 (ja) * | 2017-04-04 | 2022-08-01 | キヤノンメディカルシステムズ株式会社 | 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法 |
| EA039314B1 (ru) * | 2017-07-05 | 2022-01-12 | Биоселз (Бейдзин) Биотек Ко., Лтд. | Фармацевтически приемлемые соли полипептидов и их применение |
| WO2019006691A1 (zh) * | 2017-07-05 | 2019-01-10 | 拜西欧斯（北京）生物技术有限公司 | 用于治疗、改善或预防脑出血的肽及其用途 |
| WO2019061395A1 (zh) * | 2017-09-30 | 2019-04-04 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽组合物 |
| US12122811B2 (en) | 2018-04-06 | 2024-10-22 | Northwestern University | BDNF mimetic peptide amphiphiles |
| JP7158904B2 (ja) * | 2018-06-14 | 2022-10-24 | 社会福祉法人 恩賜財団済生会熊本病院 | 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| CN115279797A (zh) * | 2020-01-09 | 2022-11-01 | 诺诺公司 | 用于治疗中风和相关疾病的抗纤溶酶肽 |
| MX2022010160A (es) * | 2020-02-19 | 2022-10-10 | Nono Inc | Tratamiento de combinación de apoplejia con inhibidor de psd-95 escindible por plasmina y reperfusión. |
| US20230285504A1 (en) * | 2020-02-19 | 2023-09-14 | Nono Inc. | Inhibition of reperfusion injury with a psd-95 inhibitor |
| CN113735938B (zh) * | 2021-07-30 | 2024-11-08 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
| WO2023192848A1 (en) * | 2022-03-28 | 2023-10-05 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| CN120344552A (zh) | 2023-01-09 | 2025-07-18 | 北京拓界生物医药科技有限公司 | 一种神经保护性psd-95多肽抑制剂及其应用 |
| CN117422722B (zh) * | 2023-12-19 | 2024-03-29 | 北京智源人工智能研究院 | 基于adc图像的肿瘤预后特征评估的方法和装置 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2742152B1 (fr) | 1995-12-06 | 1998-01-16 | Synthelabo | Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique |
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6903184B1 (en) | 1998-03-02 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| AU2004233862A1 (en) | 2003-04-25 | 2004-11-11 | Mitos Pharmaceuticals, Inc. | Prophylactic pretreatment with antioxidants |
| PL1622639T3 (pl) | 2003-05-02 | 2013-06-28 | Lundbeck H As | Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu |
| EP1633305A2 (en) * | 2003-05-19 | 2006-03-15 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| ES2804424T3 (es) | 2006-07-11 | 2021-02-08 | Nono Inc | Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
| EP2120987B1 (en) * | 2007-03-02 | 2014-01-15 | NoNO Inc. | Treating stroke and other diseases without inhibiting n-type calcium channels |
| GB0707348D0 (en) | 2007-04-17 | 2007-05-23 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| CN101855235B (zh) | 2007-10-29 | 2013-04-24 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| NZ600205A (en) | 2008-01-25 | 2013-12-20 | Univ Aarhus | Selective exosite inhibition of papp-a activity against igfbp-4 |
| PL2320927T3 (pl) | 2008-07-09 | 2016-02-29 | Univ Copenhagen | Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD |
| DE102008037564A1 (de) | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| CA2665302A1 (en) | 2009-05-01 | 2010-11-01 | Universite De Montreal | Cd36 modulation and uses thereof |
| AU2010259986B2 (en) | 2009-06-10 | 2015-04-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| BRPI1010718A2 (pt) | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
| US20110144029A1 (en) | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
| KR102022116B1 (ko) | 2011-06-24 | 2019-09-18 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| KR102114490B1 (ko) | 2011-12-13 | 2020-05-25 | 노노 인코포레이티드 | 지주막하 출혈 및 허혈에 대한 치료법 |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
-
2012
- 2012-06-23 KR KR1020147001639A patent/KR102022116B1/ko not_active Expired - Fee Related
- 2012-06-23 EP EP18190827.8A patent/EP3427748B1/en active Active
- 2012-06-23 ES ES12802409.8T patent/ES2690994T3/es active Active
- 2012-06-23 PL PL12802409T patent/PL2723363T3/pl unknown
- 2012-06-23 HR HRP20220519TT patent/HRP20220519T1/hr unknown
- 2012-06-23 KR KR1020217026955A patent/KR102425466B1/ko active Active
- 2012-06-23 DK DK12802409.8T patent/DK2723363T3/en active
- 2012-06-23 EP EP12802409.8A patent/EP2723363B1/en active Active
- 2012-06-23 JP JP2014516487A patent/JP6401057B2/ja not_active Expired - Fee Related
- 2012-06-23 KR KR1020227025470A patent/KR20220106862A/ko active Pending
- 2012-06-23 US US14/128,941 patent/US10064910B2/en active Active
- 2012-06-23 DK DK18190827.8T patent/DK3427748T3/da active
- 2012-06-23 PT PT181908278T patent/PT3427748T/pt unknown
- 2012-06-23 HU HUE18190827A patent/HUE058238T2/hu unknown
- 2012-06-23 LT LTEP12802409.8T patent/LT2723363T/lt unknown
- 2012-06-23 SI SI201231412T patent/SI2723363T1/sl unknown
- 2012-06-23 CN CN201280031302.4A patent/CN103648518B/zh not_active Expired - Fee Related
- 2012-06-23 HU HUE12802409A patent/HUE040564T2/hu unknown
- 2012-06-23 SM SM20180592T patent/SMT201800592T1/it unknown
- 2012-06-23 CA CA2839630A patent/CA2839630A1/en active Pending
- 2012-06-23 AU AU2012274910A patent/AU2012274910B2/en active Active
- 2012-06-23 EP EP22157256.3A patent/EP4052721A1/en not_active Withdrawn
- 2012-06-23 RS RS20181182A patent/RS57798B1/sr unknown
- 2012-06-23 KR KR1020197026571A patent/KR102140169B1/ko not_active Expired - Fee Related
- 2012-06-23 ES ES18190827T patent/ES2912042T3/es active Active
- 2012-06-23 PT PT12802409T patent/PT2723363T/pt unknown
- 2012-06-23 PL PL18190827T patent/PL3427748T3/pl unknown
- 2012-06-23 HR HRP20181526TT patent/HRP20181526T1/hr unknown
- 2012-06-23 KR KR1020207021829A patent/KR102296106B1/ko not_active Expired - Fee Related
- 2012-06-23 WO PCT/IB2012/053178 patent/WO2012176172A2/en not_active Ceased
-
2017
- 2017-04-05 JP JP2017074975A patent/JP2017193535A/ja active Pending
-
2018
- 2018-08-01 US US16/051,971 patent/US10967041B2/en not_active Expired - Fee Related
- 2018-10-30 JP JP2018204034A patent/JP7085457B2/ja active Active
- 2018-11-28 CY CY20181101260T patent/CY1121379T1/el unknown
-
2020
- 2020-08-06 JP JP2020134150A patent/JP7143374B2/ja active Active
-
2021
- 2021-02-17 US US17/177,970 patent/US11878044B2/en active Active
-
2022
- 2022-09-14 JP JP2022146191A patent/JP2022188068A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220519T1 (hr) | Kombinacijska terapija ishemije | |
| Wu et al. | Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury | |
| Fröhlich et al. | Myocardial reperfusion injury: looking beyond primary PCI | |
| Keep et al. | Blood-brain barrier function in intracerebral hemorrhage | |
| Hausenloy et al. | Myocardial ischemia-reperfusion injury: a neglected therapeutic target | |
| Gauberti et al. | Thrombolytic strategies for ischemic stroke in the thrombectomy era | |
| JP2014520142A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| UA112985C2 (uk) | Одноланцюговий поліпептидний гібридний білок | |
| JP2012523438A5 (enExample) | ||
| JP2014511698A5 (enExample) | ||
| Sonni et al. | New avenues for treatment of intracranial hemorrhage | |
| Simkhada et al. | Purification, biochemical properties and antithrombotic effect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model | |
| EP2800575A1 (en) | Therapy for subarachnoid hemorrhage and ischemia | |
| Jeong et al. | Neuroprotective effect of PEP-1-peroxiredoxin2 on CA1 regions in the hippocampus against ischemic insult | |
| Li et al. | Proper heat shock pretreatment reduces acute liver injury induced by carbon tetrachloride and accelerates liver repair in mice | |
| Elbadawi et al. | Impact of remote ischemic postconditioning during primary percutaneous coronary intervention on left ventricular remodeling after anterior wall ST-segment elevation myocardial infarction: a single-center experience | |
| CN112079933A (zh) | 一种多肽类似物及其在干预治疗脑出血药物中的应用 | |
| CN107177580B (zh) | 一种广谱新型嵌合裂解酶GBS-PlySb及其编码基因和应用 | |
| WO2016078549A1 (zh) | 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用 | |
| Maguire | Stem cells part of the innate and adaptive immune systems as a therapeutic for Covid-19 | |
| Tu et al. | GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation | |
| CN101015686B (zh) | 一种溶栓药物增效剂及其制备方法 | |
| CN102268069B (zh) | 基质金属蛋白酶-9多肽抑制剂4及其应用 | |
| Douglas et al. | The relationship between cerebral reperfusion and regional expression of matrix metalloproteinase-9 in rat brain following focal cerebral ischemia |